Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
Recce Pharmaceuticals Ltd is a biotechnology company focused on developing novel anti-infective therapies for serious infections, particularly those caused by antibiotic-resistant bacteria. Its lead product candidate, REC-2282, is in clinical trials targeting severe bacterial infections, which positions the company in a niche market with high unmet medical needs.
Recce Pharmaceuticals primarily generates revenue through partnerships and collaborations with larger pharmaceutical companies for the development of its drug candidates. The company has no current revenue from product sales, relying on funding from grants and investors to support its R&D efforts. Its competitive advantage lies in its proprietary platform technology that enables the rapid development of new antibiotics, particularly in an era of rising antibiotic resistance.
Progress in clinical trials for REC-2282, particularly Phase II results
Partnership announcements with larger pharmaceutical companies
Regulatory approvals or advancements in drug development
Market sentiment regarding antibiotic resistance and funding for biotech
Regulatory changes that could impact drug approval processes
Technological disruption in antibiotic development
Emergence of new antibiotic therapies from competitors
Potential for larger pharmaceutical companies to outpace Recce in R&D
High cash burn rate with no current revenue
Dependence on external funding and partnerships
low - The biotechnology sector is generally less sensitive to economic cycles as healthcare spending tends to remain stable regardless of economic conditions.
Interest rates can affect Recce's ability to raise capital for R&D, as higher rates may increase financing costs and reduce investor appetite for biotech stocks, which are often seen as higher risk.
minimal - The company has a negative debt/equity ratio, indicating it is not reliant on debt financing.
growth - Investors looking for high-risk, high-reward opportunities in the biotech sector.
high - The stock is likely to experience significant volatility due to the binary nature of clinical trial outcomes.
